Business Description
Dicot Pharma AB
ISIN : SE0011178458
Compare
Compare
Traded in other countries / regions
DICOT.SwedenKN0.GermanyDCOIF.USA IPO Date
2018-06-20Description
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation better than existing preparations. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects and also used in the treatment of erectile dysfunction and premature ejaculation.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.63 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 45.7 | |||||
| 3-Year EPS without NRI Growth Rate | 41.7 | |||||
| 3-Year FCF Growth Rate | 43.9 | |||||
| 3-Year Book Growth Rate | -42.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.79 | |||||
| 9-Day RSI | 47.96 | |||||
| 14-Day RSI | 46.23 | |||||
| 6-1 Month Momentum % | -6.45 | |||||
| 12-1 Month Momentum % | 103.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.67 | |||||
| Quick Ratio | 1.98 | |||||
| Cash Ratio | 1.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -128.3 | |||||
| Shareholder Yield % | -4.96 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -133.95 | |||||
| ROA % | -111.43 | |||||
| ROIC % | -760.62 | |||||
| ROC (Joel Greenblatt) % | -63425.74 | |||||
| ROCE % | -134.75 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 10.9 | |||||
| Price-to-Tangible-Book | 8.6 | |||||
| EV-to-EBIT | -5.43 | |||||
| EV-to-EBITDA | -5.43 | |||||
| EV-to-FCF | -5.63 | |||||
| Price-to-Net-Current-Asset-Value | 8.6 | |||||
| Price-to-Net-Cash | 17.2 | |||||
| Earnings Yield (Greenblatt) % | -18.42 | |||||
| FCF Yield % | -17.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dicot Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.052 | ||
| Beta | 0 | ||
| Volatility % | 123.72 | ||
| 14-Day RSI | 46.23 | ||
| 14-Day ATR (kr) | 0.015838 | ||
| 20-Day SMA (kr) | 0.16917 | ||
| 12-1 Month Momentum % | 103.42 | ||
| 52-Week Range (kr) | 0.070605 - 0.423635 | ||
| Shares Outstanding (Mil) | 1,716.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dicot Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dicot Pharma AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dicot Pharma AB Frequently Asked Questions
What is Dicot Pharma AB(XSAT:DICOT)'s stock price today?
The current price of XSAT:DICOT is kr0.17. The 52 week high of XSAT:DICOT is kr0.42 and 52 week low is kr0.07.
When is next earnings date of Dicot Pharma AB(XSAT:DICOT)?
The next earnings date of Dicot Pharma AB(XSAT:DICOT) is 2024-10-31.
Does Dicot Pharma AB(XSAT:DICOT) pay dividends? If so, how much?
Dicot Pharma AB(XSAT:DICOT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers